Barbara  Kahn net worth and biography

Barbara Kahn Biography and Net Worth

Director of DexCom
Barbara Kahn is the Patty and Jay J. Baker Professor of Marketing at The Wharton School at the University of Pennsylvania. Prior to rejoining Wharton, Ms. Kahn served for three and a half years as the Dean and Schein Family Chair Professor of Marketing at the School of Business Administration, University of Miami. While Dean at the University of Miami, she launched new global initiatives and academic programs, attracted top faculty from some the of the world’s leading business schools to enhance the caliber of the school’s research and teaching, and established new partnerships with the business community. Before becoming Dean at the University of Miami, Ms. Kahn spent 17 years at The Wharton School as the Dorothy Silberberg Professor of Marketing and served as Vice Dean and Director of the Wharton undergraduate program. Ms. Kahn was also a Senior Fellow of the Leonard Davis Institute and a faculty member of the Graduate Group in the Psychology Department.

Ms. Kahn is an internationally recognized scholar on variety seeking, brand loyalty, retail assortment issues and patient decision-making whose research provides marketing managers with better understanding of the consumer choice process. She has published more than 60 articles in leading academic journals. Ms. Kahn has been elected president of the Association of Consumer Research, president of the Journal of Consumer Research Policy Board and selected as a Marketing Science Institute Trustee. Ms. Kahn served as area editor at Marketing Science and associate editor at the Journal of Consumer Research, as well as serving on or having served on the editorial boards of the Journal of Marketing Research, Marketing Science, the Journal of Marketing, the Journal of Consumer Research, the Journal of Behavioral Decision Making and Marketing Letters. She has been elected a Fellow of the Association of Consumer Research and a Fellow of Society for Consumer Psychology.

What is Barbara Kahn's net worth?

The estimated net worth of Barbara Kahn is at least $91,795.68 as of June 10th, 2020. Ms. Kahn owns 787 shares of DexCom stock worth more than $91,796 as of June 20th. This net worth evaluation does not reflect any other assets that Ms. Kahn may own. Learn More about Barbara Kahn's net worth.

How do I contact Barbara Kahn?

The corporate mailing address for Ms. Kahn and other DexCom executives is 6340 SEQUENCE DRIVE, SAN DIEGO CA, 92121. DexCom can also be reached via phone at (858) 200-0200 and via email at [email protected]. Learn More on Barbara Kahn's contact information.

Has Barbara Kahn been buying or selling shares of DexCom?

Barbara Kahn has not been actively trading shares of DexCom during the past quarter. Most recently, Barbara Kahn sold 4,666 shares of the business's stock in a transaction on Thursday, February 10th. The shares were sold at an average price of $442.35, for a transaction totalling $2,064,005.10. Learn More on Barbara Kahn's trading history.

Who are DexCom's active insiders?

DexCom's insider roster includes Donald Abbey (EVP), Steven Altman (Director), Nicholas Augustinos (Director), Andrew Balo (Insider), Quentin Blackford (COO), Michael Brown (EVP), Richard Collins (Director), Matthew Dolan (SVP), Richard Doubleday (EVP), Paul Flynn (EVP), Mark Foletta (Director), Bridgette Heller (Director), Barbara Kahn (Director), Jacob Leach (EVP), Jeffrey Moy (EVP), Patrick Murphy (EVP), Steven Pacelli (Insider), Chad Patterson (EVP), Barry Regan (EVP), Kevin Sayer (CEO), Shelly Selvaraj (SVP), Sumi Shrishrimal (SVP), Jay Skyler (Director), Sadie Stern (EVP), and Jereme Sylvain (CAO). Learn More on DexCom's active insiders.

Are insiders buying or selling shares of DexCom?

During the last twelve months, insiders at the medical device company sold shares 39 times. They sold a total of 265,317 shares worth more than $34,660,713.42. The most recent insider tranaction occured on June, 14th when Director Bridgette P Heller sold 1,000 shares worth more than $113,550.00. Insiders at DexCom own 0.3% of the company. Learn More about insider trades at DexCom.

Information on this page was last updated on 6/14/2024.

Barbara Kahn Insider Trading History at DexCom

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/10/2022Sell4,666$442.35$2,064,005.10View SEC Filing Icon  
6/10/2020Sell7,000$380.71$2,664,970.00787View SEC Filing Icon  
12/12/2019Sell9,000$205.14$1,846,260.002,613View SEC Filing Icon  
1/14/2019Sell10,631$142.30$1,512,791.30View SEC Filing Icon  
11/20/2017Sell3,000$54.58$163,740.004,353View SEC Filing Icon  
8/8/2016Sell6,000$90.52$543,120.0012,291View SEC Filing Icon  
5/12/2016Sell3,000$60.72$182,160.0042,804View SEC Filing Icon  
3/7/2016Sell5,000$67.04$335,200.0045,804View SEC Filing Icon  
8/28/2014Sell4,000$44.52$178,080.00View SEC Filing Icon  
8/21/2014Sell2,200$43.42$95,524.00View SEC Filing Icon  
See Full Table

Barbara Kahn Buying and Selling Activity at DexCom

This chart shows Barbara Kahn's buying and selling at DexCom by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

DexCom Company Overview

DexCom logo
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $116.64
Low: $116.13
High: $117.49

50 Day Range

MA: $126.16
Low: $113.81
High: $139.62

2 Week Range

Now: $116.64
Low: $74.75
High: $142.00


2,192,895 shs

Average Volume

2,732,992 shs

Market Capitalization

$46.39 billion

P/E Ratio


Dividend Yield